Search

Now showing items 11-20 of 31

The management of tuberculous pericardial effusion: Experience in 233 consecutive patients

Reuter H.; Burgess L.J.; Louw V.J.; Doubell A.F. (2007)

Aim: We report on the 30-day and one-year outcome of consecutive effusive pericarditis patients, including those with tuberculous pericarditis, over a six-year-period. Methods and Results: Patients with large pericardial ...

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

Appel, G. B.; Contreras, G.; Dooley, M. A.; Ginzler, E. M.; Isenberg, D.; Jayne, D.; Li, L-S.; Mysler, E.; Sanchez-Guerrero, J.; Solomons, N.; Wofsy, D.; Abud, C.; Adler, S.; Alarcon, G.; Albuquerque, E.; Almeida, F.; Alvarellos, A.; Appel, G.; Avila, H.; Blume, C.; Boletis, I.; Bonnardeaux, A.; Braun, A.; Buyon, J.; Cervera, R.; Chen, N.; Chen, S.; Da Costa, A. G.; Davids, M. R.; D'Cruz, D.; De Ramon, E.; Deodhar, A.; Doria, A.; Dussol, B.; Emery, P.; Fiechtner, J.; Floege, J.; Fragoso-Loyo, H.; Furie, R.; Ghazalli, R.; Ghossein, C.; Gilkeson, G.; Ginzler, E.; Gordon, C.; Grossman, J.; Gu, J.; Guillevin, L.; Hatron, P. Y.; Herrera, G.; Hiepe, F.; Houssiau, F.; Hubscher, O.; Hura, C.; Kaplan, J.; Kirsztajn, G.; Kiss, E.; Kutty, G. A.; Laville, M.; Lazaro, M.; Lenz, O.; Li, L.; Lightstone, L.; Lim, S.; Malaise, M.; Manzi, S.; Marcos, J.; Meyer, O.; Monge, P.; Naicker, S.; Neal, N.; Neuwelt, M.; Nicholls, K.; Olsen, N.; Ordi-Ros, J.; Ostrov, B.; Pestana, M.; Petri, M.; Pokorny, G.; Pourrat, J.; Qian, J.; Radhakrishnan, J.; Rovin, B.; Roman, J. S.; Shanahan, J.; Shergy, W.; Skopouli, F.; Spindler, A.; Striebich, C.; Sundel, R.; Swanepoel, C.; Si, Y. T.; Tate, G.; Tesar, V.; Tikly, M.; Wang, H.; Yahya, R.; Yu, X.; Zhang, F.; Zoruba, D. (2009)

Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these therapies have not been compared in an international ...

Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebo-controlled, double-blind clinical trials

Boffard K.D.; Riou B.; Warren B.; Choong P.I.T.; Rizoli S.; Rossaint R.; Axelsen M.; Kluger Y.; Champion H.R.; Lucas C.; Thompson E.; Ross S.; Jurkovich G.J.; Lynn M.; Pitts L.; Croce M.A. (2005)

Background: Uncontrolled bleeding is a leading cause of death in trauma. Two randomized, placebo-controlled, double-blind trials (one in blunt trauma and one in penetrating trauma) were conducted simultaneously to evaluate ...

Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study

Janssen J.P.; Collier G.; Astoul P.; Tassi G.F.; Noppen M.; Rodriguez-Panadero F.; Loddenkemper R.; Herth F.J.; Gasparini S.; Marquette C.H.; Becke B.; Froudarakis M.E.; Driesen P.; Bolliger C.T.; Tschopp J.-M. (2007)

Background: Talc is the most effective chemical pleurodesis agent for patients with malignant pleural effusion. However, concerns have arisen about the safety of intrapleural application of talc, after reports of development ...

A nicotine mouth spray for smoking cessation: A pilot study of preference, safety and efficacy

Bolliger C.T.; Van Biljon X.; Axelsson A. (2007)

Background: Various formulations of nicotine replacement therapy are commercially available. Objectives: It was the aim of this study to test preference, safety and efficacy of a new nicotine mouth spray (1 mg/actuation; ...

Kaposi's sarcoma in kidney transplant recipients: A 23-year experience

Moosa M.R. (2005)

Background: Kaposi's sarcoma (KS) is a relatively common malignancy after kidney transplantation, accounting for up to 80% of all malignancies in developing countries. Aim: To assess the frequency of KS in renal transplant ...

Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: A 24-week randomized, double-blind, placebo-controlled trial

Goodwin G.M.; Emsley R.; Rembry S.; Rouillon F. (2009)

Objective: This study evaluates the efficacy of agomelatine, the first antidepressant that is an agonist at MT1/MT2 receptors and an antagonist at 5-HT2C receptor, in the prevention of relapse of depression following ...

A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia

Emsley R.; Turner H.J.; Schronen J.; Botha K.; Smit R.; Oosthuizen P.P. (2004)

Background: While the atypical antipsychotics should ultimately reduce the prevalence of tardive dyskinesia, it is likely to remain a significant clinical problem for a long time to come. No strategy has clearly emerged ...

Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study

Davidson M.; Emsley R.; Kramer M.; Ford L.; Pan G.; Lim P.; Eerdekens M. (2007)

Background: Paliperidone extended-release tablet (paliperidone ER) is an oral psychotropic agent developed for schizophrenia treatment. Paliperidone (9-OH-risperidone, metabolite of risperidone), when used with OROS ...

Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agentsTime to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents

Diacon A.H.; Maritz J.S.; Venter A.; Van Helden P.D.; Andries K.; McNeeley D.F.; Donald P.R.; Diacon A.H.; Maritz J.S.; Venter A.; Van Helden P.D.; Andries K.; McNeeley D.F.; Donald P.R. (2010)

Evaluation of early bactericidal activity (EBA) by the determination of a fall in viable colony-forming units (CFU) of Mycobacterium tuberculosis in sputum is a first step in the clinical study of new antituberculosis ...